➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Merck
AstraZeneca
Baxter
Medtronic

Last Updated: August 5, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR OZANIMOD HYDROCHLORIDE

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Ozanimod Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02531113 ↗ Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease Active, not recruiting Celgene Phase 2 2015-09-01 The purpose is to determine whether RPC1063 is effective in the treatment of Crohn's disease.
NCT02531126 ↗ Open-Label Extension of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis Recruiting Celgene Phase 3 2015-08-01 The purpose of the trial is to determine the safety and efficacy of RPC1063 in patients diagnosed with moderate to severe ulcerative colitis.
NCT02576717 ↗ A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis Enrolling by invitation Celgene Phase 3 2015-10-01 The purpose of the trial is to determine the safety and efficacy of RPC1063 in patients with relapsing multiple sclerosis.
NCT03440372 ↗ Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease Recruiting Celgene Phase 3 2018-02-27 This is a Phase 3, randomized, double-blind, placebo-controlled study to explore the effect of oral ozanimod as an induction treatment for subjects with moderately to severely active Crohn's Disease.
NCT03440385 ↗ Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease Recruiting Celgene Phase 3 2018-03-07 This is a Phase 3, randomized, double-blind, placebo-controlled study to explore the effect of oral ozanimod as an induction treatment for subjects with moderately to severely active Crohn's Disease.
NCT03464097 ↗ A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease Not yet recruiting Celgene Phase 3 2018-07-31 This is a Phase 3, randomized, double-blind, placebo-controlled study to demonstrate the effect of oral ozanimod as maintenance therapy in subjects with moderately to severely active Crohn's Disease.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ozanimod Hydrochloride

Condition Name

Condition Name for Ozanimod Hydrochloride
Intervention Trials
Healthy Volunteers 4
Crohn Disease 4
Healthy Volunteer 3
Multiple Sclerosis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Ozanimod Hydrochloride
Intervention Trials
Crohn Disease 5
Colitis 2
Sclerosis 2
Multiple Sclerosis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Ozanimod Hydrochloride

Trials by Country

Trials by Country for Ozanimod Hydrochloride
Location Trials
United States 108
Canada 12
Australia 11
Brazil 8
Ukraine 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Ozanimod Hydrochloride
Location Trials
Texas 9
California 7
Florida 7
Louisiana 5
Illinois 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Ozanimod Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Ozanimod Hydrochloride
Clinical Trial Phase Trials
Phase 3 7
Phase 2/Phase 3 1
Phase 2 2
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Ozanimod Hydrochloride
Clinical Trial Phase Trials
Not yet recruiting 8
Recruiting 6
Enrolling by invitation 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Ozanimod Hydrochloride

Sponsor Name

Sponsor Name for Ozanimod Hydrochloride
Sponsor Trials
Celgene 17
Bristol-Myers Squibb 1
Fran├žois Lellouche 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Ozanimod Hydrochloride
Sponsor Trials
Industry 18
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Harvard Business School
Mallinckrodt
Baxter
AstraZeneca
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.